Morgan Stanley
ANTX icon

Morgan Stanley’s AN2 Therapeutics ANTX Stock Holding History

Morgan Stanley’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$801K Buy
234,187
+4,417
+2% +$9.12K ﹤0.01% 5257
2025
Q4 		$262K Buy
229,770
+39,000
+20% +$45.6K ﹤0.01% 5816
2025
Q3 		$242K Buy
190,770
+12,527
+7% +$14.3K ﹤0.01% 5814
2025
Q2 		$189K Buy
178,243
+177,943
+59,314% +$212K ﹤0.01% 5871
2025
Q1 		$408 Hold
300
– – ﹤0.01% 7401
2024
Q4 		$414 Sell
300
-3
-1% -$4 ﹤0.01% 7363
2024
Q3 		$324 Sell
303
-17,158
-98% -$29.8K ﹤0.01% 7345
2024
Q2 		$37.5K Buy
17,461
+13,297
+319% +$31.7K ﹤0.01% 6260
2024
Q1 		$13.5K Sell
4,164
-2,498
-37% -$27.2K ﹤0.01% 6590
2023
Q4 		$137K Buy
6,662
+3,877
+139% +$64.9K ﹤0.01% 6068
2023
Q3 		$44.8K Sell
2,785
-39,457
-93% -$447K ﹤0.01% 6211
2023
Q2 		$359K Sell
42,242
-3,290
-7% -$23.7K ﹤0.01% 5382
2023
Q1 		$449K Buy
45,532
+4,227
+10% +$47K ﹤0.01% 5320
2022
Q4 		$394K Buy
41,305
+1,072
+3% +$14.4K ﹤0.01% 5358
2022
Q3 		$699K Sell
40,233
-98
-0.2% -$1.14K ﹤0.01% 5095
2022
Q2 		$313K Buy
40,331
+39,446
+4,457% +$522K ﹤0.01% 5660
2022
Q1 		$14K Buy
+885
New +$13.4K ﹤0.01% 7278

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Morgan Stanley's ANTX Position: Q1 2026 in Review

Morgan Stanley increased its AN2 Therapeutics (ANTX) stake by 1.9% in Q1 2026, buying an estimated $9.12K and bringing the position to 234,187 shares worth $801K. The position accounts for ﹤0.01% of the portfolio, ranked #5257.

Morgan Stanley first reported a position in ANTX in Q1 2022 and has held it in 17 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Morgan Stanley held 234,187 shares of AN2 Therapeutics worth $801K as of Q1 2026.
  • Morgan Stanley bought 4,417 AN2 Therapeutics shares in Q1 2026, an estimated $9.12K.
  • AN2 Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5257 holding.
  • Morgan Stanley first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.